Given the urgency and gravity of the decision to reverse anticoagulation, it is important for pharmacists to be aware of the key patient-specific factors that will influence patient safety. While some clinical scenarios necessitate anticoagulation reversal, these are accompanied by the potential for further complications. Using patient cases, this interactive session will provide a comprehensive overview of the various strategies for individual anticoagulant reversal, including agent selection, laboratory monitoring, and pharmacokinetic data while initially weighing the risk versus benefit of anticoagulation reversal and the approach to agent selection. New and emerging data that may influence clinical and operational pharmacy decisions (e.g., agents, formulary management) will also be presented.
This activity is approved for Board Certified Critical Care Pharmacist (BCCCP) and Board Certified Emergency Medicine Pharmacist (BCEMP) recertification credit.
The BCCCP/BCEMP Clinical Sessions are part of the professional development program for the recertification of board-certified Critical Care and Emergency Medicine pharmacists by the Board of Pharmacy Specialties and jointly provided by ACCP and the American Society of Health-System Pharmacists (ASHP). In order to earn the BCCCP/BCEMP recertification credit, participants must attend the session, claim the continuing pharmacy education credit, and pass the associated posttest. Access to the BCOP Clinical Sessions posttests will be available on December 18, 2024, at www.accp.com/myaccount to anyone who has purchased access to the BCCCP or BCEMP posttests. For participants who have not purchased access to the posttest, access can be purchased until 5:30 p.m. on Tuesday, October 15, at the ACCP Registration Desk. The deadline to submit posttests for these sessions will be December 16, 2025.